Use of Intravenous Recombinant Tissue Plasminogen activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke

This study represents the largest clinical experience of stroke thrombolysis in patients receiving NOACs before stroke. rt-PA appears to be reasonably well tolerated without prohibitive risks for adverse events among selected NOAC-treated patients. However, our observations must be considered as preliminary because of the absence of coagulation parameters, timing of the last NOAC intake, and whether nonspecific reversal strategies may have been applied.